HepaTx Develops a New Treatment for Liver

Gil Seton is a real estate investment expert with more than three decades of professional experience in the industry. Since 2003, Gil Seton has served as manager of SP Investment Fund, LLC in Los Angeles, California. The company invests in affordable housing communities and has expanded into investing in early stage technology and biotechnology startups, including HepaTx.

A biotechnology company specializing in creating stem-cell treatments that will provide an alternative to liver transplants, HepaTx developed an innovative therapy for end-stage liver diseases that can potentially save lives. The existing gold standard treatment for severe liver disease (organ transplant) is expensive and only available to a fraction of the population who need the treatment.

According to HepaTx findings, a direct infusion of stem cells into the liver can replace diseases and dead liver cells. Once the stem cells are manufactured, they can be banked and distributed to hospitals and facilities where they can be used. Tests using mouse models have proven zero tumor risks and shown promising physiological efficacy of the infused stem cells (hepatocytes).

The new therapy, SF-Heps, is a licensed three-part process. It starts with isolating stem cells from discarded lipoaspirate, followed by manipulating the chemical compound of the cells into functional liver cells. The last step involves the infusion of modified stem cells into portal veins for engraftment.